2 active not recruiting, 2 completed, 2 recruiting, 1 enrolling by invitation. 4 Phase 2, 4 Phase 3, 3 Phase 1.
Follow Povetacicept: new trials by email Literature Review of Povetacicept trials Research Report on Povetacicept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy | Phase 3 | Not yet recruiting | Vertex Pharmaceuticals Incorporated | 40 | 2026-10-23 | 2026-10-22 |
| A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy Povetacicept - Immunoglobulin A Nephropathy | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 605 | 2026-09-17 | 2026-10-19 |
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Povetacicept, Placebo - Myasthenia Gravis, Generalized | Phase 2 | Recruiting | Vertex Pharmaceuticals Incorporated | 30 | 2026-05-13 | 2026-09-11 |
| Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) Povetacicept, Tacrolimus - Primary Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | 176 | 2025-09-30 | 2026-09-18 |
| A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations Povetacicept - Healthy Volunteers | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 136 | 2025-06-06 | 2025-09-18 |
| Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) Povetacicept, Placebo (matched to Povetacicept) - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 605 | 2024-08-30 | 2026-05-15 |
| An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Povetacicept - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 1 / Phase 2 | Completed | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 30 | 2023-07-03 | 2026-09-14 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
Glomerulonephritis, IGA (4) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Autoimmune (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Churg-Strauss Syndrome (1) · Glomerulonephritis (1) · Glomerulonephritis, Membranous (1) · Granulomatosis with Polyangiitis (1) · Lupus Nephritis (1) · Microscopic Polyangiitis (1) · Myasthenia Gravis (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Vertex Pharmaceuticals Incorporated (5) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (2) · Alpine Immune Sciences, Inc. (1)
United States (7) · Australia (5) · United Kingdom (4) · Germany (3) · Italy (3) · South Korea (3) · Spain (3) · Turkey (Türkiye) (3) · Austria (2) · Brazil (2) · Canada (2) · China (2) · Czechia (2) · Hungary (2) · Ireland (2)
2025 (3), 2023 (1)